



**PATENT** 

Client-Matter No.: CROL-156

(056290.0103)

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	<b>Application of:</b>	Kevin R. Stone	)	Group Art Unit: 1653
Seria	l No.:	10/722,869	)	Examiner: Mayer, Suzanne Marie
Filed	•	November 26, 2003	)	
For:	<b>SUBSTANTIAI</b>	LLY NON-IMMUNOGENIC	)	
	INJECTABLE (	COLLAGEN	)	

#### **CERTIFICATE OF MAILING (37 C.F.R. § 1.8)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to MAIL STOP PETITION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the

date indicated below.

Date: 3/23/65

Angelo J. Magnanelli

#### MAIL STOP PETITION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

#### TRANSMITTAL LETTER

Enclosed herewith for filing in connection with the above-identified patent application are the following:

- 1. Petition Pursuant to 37 C.F.R. § 1.78 to Accept an Unintentional Delay for Claim of Priority Under 35 U.S.C. §§ 1.19(e) and 120;
- 2. Supplemental Amendment;
- Copy of the Utility Patent Application Transmittal (Small Entity) filed on November 26, 2003;
  - 4. A copy of the Official Filing Receipt mailed on March 10, 2004; and
  - 5. Return Postcard.

The PTO did not receive the following listed Item(s). Pertition would 37 C. F. R.
1.78

Kevin R. Stone U.S.S.N. 10/722,869 March 23, 2005 Page 2 of 2

The Commissioner is authorized to charge any additional fees or credit any overpayment to Deposit Account No. 50-1133.

Respectfully submitted,

Simona A. Levi-Minzi, Ph.D.

Reg. No. 43,750

Attorney for Applicant

McDermott Will & Emery LLP 28 State Street Boston MA 02109-1775 Tel (617) 535-4065 Fax (617) 535-3800

Date: March 23, 2005

MIA 294171-1.056328.0034

Junited States Patent and Trademark Office For Moderate States Patent and Trademark Office For Moderate States Policy 1908 (No. 1450 Alexandra, Viginia 22313-1450 www.uspto.gov

APPL NO.

Mark G. Lappin

28 State Street

Boston, MA 02109

McDermott, Will & Emery

**FILING OR 371** (c) DATE

ART UNIT 1653

**FIL FEE REC'D** 

OCKET NO

IND CLMS **DRAWINGS** TOT CLMS 23

**CONFIRMATION NO. 8648** 

10/722,869

11/26/2003

412

DOCKET

CROL-156 (56290-103)

3

FILING RECEIPT

OC0000000120698191

Date Mailed: 03/10/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an , error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Kevin R. Stone, Mill Valley, CA;

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/429,078 11/26/2002

Foreign Applications

If Required, Foreign Filing License Granted: 03/10/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Substantially non-immunogenic injectable collagen

**Preliminary Class** 



# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

MAR

COPY

TILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

Docket No. CROL-156 (56290-103)

Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

### TO THE COMMISSIONER FOR PATENTS

Mail Stop Patent Application P.O. Box 1450 Alexandria VA 22313-1450



Alexandria, VA 22313-1450 Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled: Substantially Non-Immunogenic Injectable Collagen and invented by: Kevin R. Stone If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information: Gentinuation Divisional Continuation-in-part (CIP) of prior application No.: 60/429,078 Which is a: Claims Priority to filed 11/26/02 □ Continuation Divisional ☐ Continuation-in-part (CIP) of prior application No.: Which is a: ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: Enclosed are: **Application Elements** 1. 

Filing fee as calculated and transmitted as described below Specification having 25 pages and including the following: a. 🔯 Descriptive Title of the Invention Cross References to Related Applications (if applicable) Statement Regarding Federally-sponsored Research/Development (if applicable) d. 🔲 Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix e. 🛛 Background of the Invention f. 🛛 Brief Summary of the Invention g. 🔲 Brief Description of the Drawings (if filed) h. 🔯 **Detailed Description** i. 🛛 Claim(s) as Classified Below j. Abstract of the Disclosure



# UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

Docket No. CROL-156 (56290-103)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

	Application Elements (Continued)						
3.		Drawing(s) (when necessary as prescribed by 35 USC 113)					
	a.	Formal Number of Sheets					
	b.	Informal Number of Sheets					
4.	$\boxtimes$	Oath or Declaration					
	a.	☐ Newly executed (original or copy) ☑ Unexecuted					
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)					
	C.	☐ With Power of Attorney ☐ Without Power of Attorney					
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).					
5.		corporation By Reference (usable if Box 4b is checked) he entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under ox 4b, is considered as being part of the disclosure of the accompanying application and is hereby corporated by reference therein.					
6.		CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)					
7.		Application Data Sheet (See 37 CFR 1.76)					
8. ·		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)					
	a.	Computer Readable Form (CFR)					
	b.	☐ Specification Sequence Listing on:					
		i. CD-ROM or CD-R (2 copies); or					
		ii. 🖸 Paper					
	C.	Statement(s) Verifying Identical Paper and Computer Readable Copy					
Accompanying Application Parts							
9.		Assignment Papers (cover sheet & document(s))					
10.	□ ·	37 CFR 3.73(B) Statement (when there is an assignee)					
11.		inglish Translation Document (if applicable)					
12.		Information Disclosure Statement/PTO-1449					
13.		Preliminary Amendment					
14.	$\boxtimes$	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)					
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)					
16.	$\boxtimes$	Certificate of Mailing					
		☐ First Class ☒ Express Mail (Specify Label No.): EL 993 167 521 US					



# UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

Docket No. CROL-156 (56290-103)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

		Accompanying Application Parts (Continued)				
17.	X	Applicant claims small entity status. See 37 CFR 1.27.  (Optional) Small Entity Statement(s) - Specify Number of Statements Submitted:				
18.		Additional Enclosures (please identify below):				
		· ·				
19.		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)  Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.  Warning				
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.				
-						



### UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. CROL-156 (56290-103)

Total Pages in this Submission



#### Fee Calculation and Transmittal

#### **CLAIMS AS FILED** For #Filed #Allowed #Extra Rate Fee Total Claims 23 - 20 = 3 \$9.00 \$27.00 Indep. Claims - 3 = 0 \$43.00 \$0.00 Multiple Dependent Claims (check if applicable) \$0.00 **BASIC FEE** \$385.00 OTHER FEE (specify purpose) \$0.00 **TOTAL FILING FEE** \$412.00 ☐ A check in the amount of to cover the filing fee is enclosed: ∑ The Director is hereby authorized to charge and credit Deposit Account No. 50–1133 as described below. Charge the amount of \$412.00 as filing fee. Credit any overpayment.

☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.

☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,

Dated: November 26, 2003

pursuant to 37 C.F.R. 1.311(b).

Signature

Mark G. Lappin, Reg. No. 26,618 McDermott, Will & Emery 28 State Street

Boston, MA 02109

CC